Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI322 in Advanced Malignant Tumors
NCT04328831Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simridarlimab in advanced malignant solid tumor, sponsored by Innovent Biologics. Primary endpoints: Number of Dose Limiting Toxicities at 28 days, Number of treatment related adverse events and 1 more. Started Jul 2020; status: completed.
02
Drugs
simridarlimab
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT04328831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328831.